Business Context and Reporting Period
This Form 8-K filing by PharmAthene, Inc. (not Altimmune, Inc.) reports on the 2012 Annual Meeting of Stockholders held on June 22, 2012. The filing details the results of votes submitted to security holders regarding director elections and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following directors were elected to serve until the 2013 annual meeting:
- John Gill: 14,488,543 votes for; 1,273,576 withheld.
- Brian A. Markison: 14,328,518 votes for; 1,433,601 withheld.
- Joel McCleary: 14,325,329 votes for; 1,436,790 withheld.
- Eric I. Richman: 14,861,764 votes for; 900,355 withheld.
- Jeffrey W. Runge, M.D.: 15,027,809 votes for; 734,310 withheld.
- Mitchel Sayare, Ph.D.: 14,329,298 votes for; 1,432,821 withheld.
- Derace L. Schaffer, M.D.: 13,981,128 votes for; 1,780,991 withheld.
- Steven St. Peter, M.D.: 14,505,609 votes for; 1,256,510 withheld.
All director nominees received significant broker non-votes (22,144,093 each). Stockholders ratified the selection of Ernst & Young LLP as independent auditors with 36,266,014 votes for, 1,619,304 against, and 20,894 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the company name is PharmAthene, Inc., as the input metadata incorrectly referenced Altimmune, Inc.
- Confirm the total number of shares entitled to vote based on the sum of votes for, withheld, and broker non-votes.
- Review the full proxy statement for details on the director nominees' qualifications and any related party transactions.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.